P
Analgesic substances that relieve pain. Painkillers come in two classes opioid and non-opioid. The non-opioid analgesics come in over the counter and prescription forms, while opioid analgesics are only available through prescription and are potentially addictive.
Introduced by Perdue Pharma in the US market in January, 2005, brand name for hydromorphone hydrochloride in time-release capsule form. Manufactured by Perdue Pharma, it is prescribed in 12, 16, 24 and 32 mg. strengths. This drug is meant for people who have built up a tolerance to other opioids such as OxyContin. If someone were to take just one of the highest strength Palladone® capsules, and they did not have a tolerance to opioids, it could be enough for an overdose. Palladone was voluntarily taken off of the market in July of 2005 because a company study showed the time release mechanism could be bypassed if someone ingested alcohol with the medication, potentially leading to a fatal overdose.
Not through the gastrointestinal route; for instance, given via intramuscular or intravenous injection.
Partial Agonists (opioid type, mu receptor):
Partial agonists possess some of the properties of both antagonists and full agonists. Partial agonists bind to receptors and activate them, but not to the same degree as do full agonists. At lower doses and in individuals who are not dependent on opioids, full agonists and partial agonists produce effects that are indistinguishable. As doses are increased, both full and partial agonists produce increasing effects. At a certain point, however, the increasing effects of partial agonists reach maximum levels and do not increase further, even if doses continue to rise—the ceiling effect. This applies to any effect mediated by mu opioid receptors (e.g., analgesia, euphoria, respiratory depression). As higher doses are reached, partial agonists can act like antagonists—occupying receptors but not activating them (or only partially activating them), while at the same time displacing or blocking full agonists from receptors.
PAWS (Post Acute Withdrawal Syndrome):
Withdrawal symptoms that continue after the initial acute withdrawal passes; The symptoms are less severe but can be long lasting. The symptoms are the result of long-term changes to the brain due to addiction. It is these withdrawal symptoms that drive many to relapse even months after drug use ends.
Structured relationship in which people meet in order to provide or exchange emotional support with others facing similar challenges. The group does not necessarily need to have healthcare providers among its members. Peer to peer groups are those such as AA, NA, smart recovery, and online line forums. Peer support by itself does not constitute treatment, but is one of the many tools that make up a treatment plan. Peer support should be used in conjunction with professional psychosocial therapy and/or medication as part of a comprehensive treatment plan.
Percocet®
Brand name for acetaminophen and oxycodone in tablet or capsule form. Manufactured by Endo Pharmaceuticals, it is prescribed for relief of moderate to moderately severe pain, including conditions accompanied by fever. Each capsule contains: Acetaminophen – 500 mg and Oxycodone HCl – 5 mg. Each tablet contains: Acetaminophen – 325 mg and Oxycodone – 5 mg.
Percodan® is a Brand name for oxycodone and asprin in tablet form. Manufactured by DuPont Pharma, Percodan is prescribed for the relief of mild to moderately severe pain, including conditions accompanied by fever and/or inflammation. Each tablet contains: Oxycodone Hydrochloride – 4.5 mg; Oxycodone Terephthalate – 0.38 mg; Aspirin, USP – 325 mg.
peripheral nervous system:
Parts of the nervous system outside of the Central Nervous System which form lines of communication between the CNS and the rest of the body.
Study of the biochemical and physiological effects of drugs and the mechanisms of their actions, including correlation of these actions and effects with the chemical structure of the drug.
Study of the action of drugs in the body over a period of time, including the processes of absorption, distribution, localization in tissues, biotransformation, and excretion.
Treatment of disease by using medicines.
Normal physiologic state of adaptation to a substance, the absence of which produces symptoms and signs of withdrawal. It is possible to be physically dependent on a substance without being addicted to it.
(Ann Intern Med. 2006;144:127-134.)
The American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine recognize the following definitions and recommend their use. see document
Physical dependence is a state of adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.
Biological study of the functions of living organisms and their parts.
Goose bumps, also called goose flesh, or the medical term cutis anserina, are the bumps on a person's skin at the base of body hairs which may involuntarily develop when a person is cold or experiences strong emotions such as fear or awe. The reflex of producing goose bumps is known as piloerection.
(pla-see'bo) A placebo is an inactive pill, liquid, powder, or other inert compound that has no treatment value. A substance or treatment that has no effect on human beings. In clinical trials, experimental treatments are often compared with placebos to assess the treatment's effectiveness. The participants in the control group will receive a placebo instead of an active drug or treatment. Also referred to as a "sugar pill."
An apparently beneficial result of therapy that occurs because of the patient’s expectation that the therapy will help, not due to any medical treatment or substance. A physical or emotional change, occurring after a substance is taken or administered, that is not the result of any special property of the substance. The change may be beneficial, reflecting the expectations of the participant and, often, the expectations of the person giving the substance.
Concurrent use or abuse of multiple substances (e.g., drinking alcohol as well as smoking tobacco, snorting cocaine, inhaling glue fumes).
Neuron receiving a signal.
Patient Physician Matching System (PPMS) It is a way for DATA-2000 certified physicians, with treatment openings, to contact patients seeking buprenorphine treatment for opioid dependence. It is a centralized list of patients from which certified physicians, in your area, can draw from when they have an opening. It is a more efficient way to help connect patient to physician.
Patient Register/login -
Physician Register/login
Precipitated withdrawal syndrome (PWS) can occur when an antagonist (or partial agonist, such as buprenorphine) is administered to a patient physically dependent on full agonist opioids, prior to the onset of initial withdrawal symptoms. Due to Buprenorphine’s high affinity and low intrinsic activity at the mu receptor, the partial antagonist displaces agonist opioids from the mu receptors, without activating the receptor to an equivalent degree, resulting in a net decrease in agonist effect, thus precipitating a withdrawal syndrome.
Neuron sending a signal.
Probuphine® is an innovative, long-term, implantable formulation of buprenorphine that is designed to provide a constant, low level of drug for six months following a single treatment. A depot formulation of buprenorphine presents intriguing prospects for populations such as prisoners, patients unable to comply with a daily dosing schedule, or to prevent diversion.
Manufacturer: Titan pharmaceuticals Status: Not yet FDA approved, currently in phase 3 studies. US patent issues all but killed the drug in 2008, but in a October 2009
press release the National Institute on Drug Abuse (
NIDA) awarded Titan a $7.6 million grant to complete phase 3 studies, suggesting that a workaround for the patent exists, such as orphan drug status perhaps. Studies are scheduled to resume 1st quarter of 2010.
Behavioral changes in patients that seem similar to those in patients with opioid dependence or addiction but are secondary to inadequate pain control.
(Ann Intern Med. 2006;144:127-134.)
pseudo-opioid resistance:
Adequate pain relief continue to report persistent severe pain to prevent reduction in current opioid analgesic dose.
(Ann Intern Med. 2006;144:127-134.)
Mind-altering substance.
Psychological dependence:
A compulsion to use a drug for its pleasurable effects. Such dependence may lead to a compulsion to misuse a drug. A craving and compulsion to use a drug that is psychologically rather than physiologically based, eg, compulsive gambling is a purely psychological dependence. Psychological dependence is sometimes called "chronic craving syndrom".
Combining psychological and social aspects.